Literature DB >> 8911003

Immunogenicity of a peptide from a major neutralising determinant of the feline immunodeficiency virus surface glycoprotein.

M A Rigby1, N Mackay, G Reid, R Osborne, J C Neil, O Jarrett.   

Abstract

The third variable region (V3) of the feline immunodeficiency virus (FIV) surface glycoprotein is predicted to have similar physical properties to that of HIV and has been shown to contain immunodominant and neutralizing epitopes. Immunological characteristics of this region were investigated further using a peptide corresponding to the middle of the putative FIV V3 loop. The peptide was recognized in ELISA by sera from the majority of naturally FIV-infected cats, and absorbed a significant fraction of the virus neutralizing activity from a pool of sera of cats naturally infected with FIV, confirming the immunogenic nature of this region. A sheep immunized with an octameric form of the peptide (multiple antigenic peptide; MAP) in Freund's complete adjuvant generated neutralizing antibody to a higher titre than infected cats. However, immunization of cats with the same MAP in an acceptable adjuvant formulation (Quil A) induced antibody and cytotoxic T-cell responses to the immunizing peptides but only minimal neutralizing activity. These responses did not significantly alter the kinetics of infection or the proviral load after challenge with a homologous strain of FIV, compared with naive controls. While the potential efficacy of peptide vaccines to lentiviruses remains to be determined, this study shows that the immune response evoked may be highly dependent on the delivery and adjuvant regime used.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8911003     DOI: 10.1016/0264-410x(96)00060-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted.

Authors:  D Matteucci; M Pistello; P Mazzetti; S Giannecchini; D Del Mauro; I Lonetti; L Zaccaro; C Pollera; S Specter; M Bendinelli
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Vaccination with a feline immunodeficiency virus multiepitopic peptide induces cell-mediated and humoral immune responses in cats, but does not confer protection.

Authors:  J N Flynn; C A Cannon; J C Neil; O Jarrett
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Sequential CD134-CXCR4 interactions in feline immunodeficiency virus (FIV): soluble CD134 activates FIV Env for CXCR4-dependent entry and reveals a cryptic neutralization epitope.

Authors:  Aymeric de Parseval; Chris K Grant; K Jagannadha Sastry; John H Elder
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

4.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: homologous erythrocytes as a delivery system for preferential immunization with putative protective antigens.

Authors:  L Chiarantini; D Matteucci; M Pistello; U Mancini; P Mazzetti; C Massi; S Giannecchini; I Lonetti; M Magnani; M Bendinelli
Journal:  Clin Diagn Lab Immunol       Date:  1998-03

5.  Kinetics of replication of a partially attenuated virus and of the challenge virus during a three-year intersubtype feline immunodeficiency virus superinfection experiment in cats.

Authors:  M Pistello; D Matteucci; G Cammarota; P Mazzetti; S Giannecchini; D Del Mauro; S Macchi; L Zaccaro; M Bendinelli
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

6.  Mapping of the CXCR4 binding site within variable region 3 of the feline immunodeficiency virus surface glycoprotein.

Authors:  Magnus Sundstrom; Rebecca L White; Aymeric de Parseval; K Jagannadha Sastry; Garrett Morris; Chris K Grant; John H Elder
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

7.  Recombination in feline immunodeficiency virus from feral and companion domestic cats.

Authors:  Jessica J Hayward; Allen G Rodrigo
Journal:  Virol J       Date:  2008-06-17       Impact factor: 4.099

8.  Immunogenicity and Efficacy of a Novel Multi-Antigenic Peptide Vaccine Based on Cross-Reactivity between Feline and Human Immunodeficiency Viruses.

Authors:  Bikash Sahay; Alek M Aranyos; Meerambika Mishra; Andrew C McAvoy; Marcus M Martin; Riuyu Pu; Sayaka Shiomitsu; Keijiro Shiomitsu; Michael J Dark; Missa P Sanou; Shannon R Roff; Mobeen H Rathore; Janet K Yamamoto
Journal:  Viruses       Date:  2019-02-03       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.